NASDAQ:AMPH Amphastar Pharmaceuticals (AMPH) Stock Forecast, Price & News $45.99 -1.31 (-2.77%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$45.68▼$47.7050-Day Range$45.51▼$65.0052-Week Range$26.76▼$67.66Volume524,136 shsAverage Volume616,318 shsMarket Capitalization$2.22 billionP/E Ratio23.58Dividend YieldN/APrice Target$70.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Amphastar Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside53.3% Upside$70.50 Price TargetShort InterestBearish7.40% of Float Sold ShortDividend StrengthN/ASustainability-2.21Upright™ Environmental ScoreNews Sentiment0.62Based on 9 Articles This WeekInsider TradingSelling Shares$5.51 M Sold Last QuarterProj. Earnings Growth30.00%From $2.50 to $3.25 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.76 out of 5 starsMedical Sector67th out of 970 stocksPharmaceutical Preparations Industry16th out of 448 stocks 3.5 Analyst's Opinion Consensus RatingAmphastar Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $70.50, Amphastar Pharmaceuticals has a forecasted upside of 53.3% from its current price of $45.99.Amount of Analyst CoverageAmphastar Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.40% of the float of Amphastar Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmphastar Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Amphastar Pharmaceuticals has recently increased by 106.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmphastar Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmphastar Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmphastar Pharmaceuticals has received a 46.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Subcutaneous human immunoglobulin", "Procainamide", "Epinephrine", and "Medroxyprogesterone acetate" products. See details.Environmental SustainabilityThe Environmental Impact score for Amphastar Pharmaceuticals is -2.21. Previous Next 2.0 News and Social Media Coverage News SentimentAmphastar Pharmaceuticals has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 8 people have searched for AMPH on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,509,514.00 in company stock.Percentage Held by Insiders28.40% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Amphastar Pharmaceuticals are expected to grow by 30.00% in the coming year, from $2.50 to $3.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amphastar Pharmaceuticals is 23.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.57.Price to Earnings Ratio vs. SectorThe P/E ratio of Amphastar Pharmaceuticals is 23.58, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 110.09.Price to Book Value per Share RatioAmphastar Pharmaceuticals has a P/B Ratio of 4.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amphastar Pharmaceuticals (NASDAQ:AMPH) StockAmphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Read More AMPH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMPH Stock News HeadlinesOctober 1, 2023 | americanbankingnews.comStockNews.com Downgrades Amphastar Pharmaceuticals (NASDAQ:AMPH) to HoldSeptember 26, 2023 | seekingalpha.comAmphastar: Dip, But No Slip, Rebound Playbook (Rating Upgrade)October 1, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 25, 2023 | finance.yahoo.comAmphastar Pharmaceuticals (AMPH) Outpaces Stock Market Gains: What You Should KnowSeptember 18, 2023 | finance.yahoo.comIs There An Opportunity With Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) 46% Undervaluation?September 14, 2023 | finance.yahoo.comShould You Invest in Amphastar (AMPH) Based on Bullish Wall Street Views?September 13, 2023 | finance.yahoo.comAmphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should KnowSeptember 13, 2023 | finance.yahoo.comAmphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior NotesOctober 1, 2023 | Legacy Research (Ad)Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”September 12, 2023 | marketwatch.comAmphastar Pharmaceuticals Shares Down 9% After Private Notes OfferingSeptember 11, 2023 | finanznachrichten.deAmphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior NotesSeptember 11, 2023 | finance.yahoo.comAmphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior NotesSeptember 9, 2023 | finance.yahoo.comInsider Sell: CFO, EVP & Treasurer William Peters Sells 60,743 Shares of Amphastar ...August 31, 2023 | finanznachrichten.deAmphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare ConferenceAugust 31, 2023 | finance.yahoo.comAmphastar Pharmaceuticals to Present at the Wells Fargo Healthcare ConferenceAugust 25, 2023 | finance.yahoo.comWith 64% institutional ownership, Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a favorite amongst the big gunsAugust 16, 2023 | markets.businessinsider.comIronwood Pharma (IRWD) Receives a Buy from Piper SandlerAugust 11, 2023 | msn.comFive IBD 50 Stocks Run Into Trouble; DraftKings Stock Faces This Critical TestAugust 11, 2023 | msn.comIs Amphastar (AMPH) a Solid Growth Stock? 3 Reasons to Think "Yes"August 11, 2023 | msn.comFive IBD 50 Stocks In TroubleAugust 10, 2023 | seekingalpha.comAmphastar Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 9, 2023 | finance.yahoo.comQ2 2023 Amphastar Pharmaceuticals Inc Earnings CallAugust 8, 2023 | finance.yahoo.comAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023August 8, 2023 | baystreet.caLilly Pops on SalesAugust 3, 2023 | finance.yahoo.comAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023August 2, 2023 | msn.comAmphastar Pharmaceuticals (AMPH) Price Target Increased by 20.00% to 67.32July 28, 2023 | msn.comAmphastar's Generic Drug Rush Gains MomentumSee More Headlines Receive AMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMPH Company Calendar Last Earnings8/08/2023Today10/01/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AMPH CUSIPN/A CIK1297184 Webwww.amphastar.com Phone(909) 980-9484Fax909-980-8296Employees1,615Year FoundedN/APrice Target and Rating Average Stock Price Forecast$70.50 High Stock Price Forecast$71.00 Low Stock Price Forecast$70.00 Forecasted Upside/Downside+53.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$1.95 Trailing P/E Ratio23.58 Forward P/E Ratio18.40 P/E GrowthN/ANet Income$91.39 million Net Margins18.85% Pretax Margin24.08% Return on Equity20.12% Return on Assets12.07% Debt Debt-to-Equity Ratio0.83 Current Ratio1.53 Quick Ratio1.11 Sales & Book Value Annual Sales$498.99 million Price / Sales4.45 Cash Flow$2.37 per share Price / Cash Flow19.44 Book Value$10.94 per share Price / Book4.20Miscellaneous Outstanding Shares48,270,000Free Float34,561,000Market Cap$2.22 billion OptionableOptionable Beta0.84 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Ziping Luo Ph.D. (Age 73)Chairman, Chief Scientist & COO Comp: $1.53MDr. Yongfeng Zhang Ph.D. (Age 76)Co-Founder, Pres, CEO, Chief Scientific Officer & Director Comp: $2.13MMr. William J. Peters M.B.A. (Age 55)CFO, Exec. VP of Fin., Treasurer & Director Comp: $1.12MMr. Jacob Liawatidewi M.B.A. (Age 49)Exec. VP of Sales, Marketing & Corp. Admin. Center, Corp. Sec. and Director Comp: $794.15kMr. Rong Zhou M.S. (Age 64)Sr. Exec. VP of Production Comp: $835.05kDan Dischner M.B.A.VP of HR & Corp. CommunicationTony Marrs M.B.A.M.P.H., Sr. VP of Regulatory Affairs & Clinical OperationsMore ExecutivesKey CompetitorsCertaraNASDAQ:CERTGoodRxNASDAQ:GDRXXenon PharmaceuticalsNASDAQ:XENEGalapagosNASDAQ:GLPGMaravai LifeSciencesNASDAQ:MRVIView All CompetitorsInsiders & InstitutionsTucker Asset Management LLCSold 3,870 shares on 9/8/2023Ownership: 0.058%William J PetersSold 60,743 sharesTotal: $3.14 M ($51.75/share)Yakob LiawatidewiSold 28,816 sharesTotal: $1.53 M ($53.13/share)Virginia Retirement Systems ET ALBought 29,300 shares on 8/22/2023Ownership: 0.061%California State Teachers Retirement SystemSold 1,652 shares on 8/21/2023Ownership: 0.096%View All Insider TransactionsView All Institutional Transactions AMPH Stock - Frequently Asked Questions Should I buy or sell Amphastar Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMPH shares. View AMPH analyst ratings or view top-rated stocks. What is Amphastar Pharmaceuticals' stock price forecast for 2023? 2 brokerages have issued twelve-month target prices for Amphastar Pharmaceuticals' shares. Their AMPH share price forecasts range from $70.00 to $71.00. On average, they predict the company's share price to reach $70.50 in the next twelve months. This suggests a possible upside of 53.3% from the stock's current price. View analysts price targets for AMPH or view top-rated stocks among Wall Street analysts. How have AMPH shares performed in 2023? Amphastar Pharmaceuticals' stock was trading at $28.02 at the beginning of the year. Since then, AMPH shares have increased by 64.1% and is now trading at $45.99. View the best growth stocks for 2023 here. Are investors shorting Amphastar Pharmaceuticals? Amphastar Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 2,690,000 shares, an increase of 106.9% from the August 31st total of 1,300,000 shares. Based on an average trading volume of 457,500 shares, the days-to-cover ratio is presently 5.9 days. Approximately 7.4% of the shares of the company are sold short. View Amphastar Pharmaceuticals' Short Interest. When is Amphastar Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our AMPH earnings forecast. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) issued its earnings results on Tuesday, August, 8th. The company reported $0.58 EPS for the quarter, topping analysts' consensus estimates of $0.52 by $0.06. The business earned $145.71 million during the quarter, compared to the consensus estimate of $137.20 million. Amphastar Pharmaceuticals had a net margin of 18.85% and a trailing twelve-month return on equity of 20.12%. What ETFs hold Amphastar Pharmaceuticals' stock? ETFs with the largest weight of Amphastar Pharmaceuticals (NASDAQ:AMPH) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Innovator IBD 50 ETF (FFTY), Janus Henderson Small Cap Growth Alpha ETF (JSML), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), ETC 6 Meridian Small Cap Equity ETF (SIXS), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and ERShares NextGen Entrepreneurs ETF (ERSX). What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO? 35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend. What other stocks do shareholders of Amphastar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT). What is Amphastar Pharmaceuticals' stock symbol? Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH." How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amphastar Pharmaceuticals' stock price today? One share of AMPH stock can currently be purchased for approximately $45.99. How much money does Amphastar Pharmaceuticals make? Amphastar Pharmaceuticals (NASDAQ:AMPH) has a market capitalization of $2.22 billion and generates $498.99 million in revenue each year. The company earns $91.39 million in net income (profit) each year or $1.95 on an earnings per share basis. How many employees does Amphastar Pharmaceuticals have? The company employs 1,615 workers across the globe. How can I contact Amphastar Pharmaceuticals? Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The official website for the company is www.amphastar.com. The company can be reached via phone at (909) 980-9484, via email at jasons@amphastar.com, or via fax at 909-980-8296. This page (NASDAQ:AMPH) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.